biotechs Archives - Page 3 of 6

End of line for StemCells Inc., pioneering & controversial stem cell biotech

May 31, 2016 / Professor Paul Knoepfler, Ph.D. / 10 Comments

A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for […]

End of line for StemCells Inc., pioneering & controversial stem cell biotech Read More »

About that Athersys stem cell stroke clinic trial PR…

February 19, 2016 / Professor Paul Knoepfler, Ph.D. / 12 Comments

There has been a lot of excitement this week about a press release from stem cell biotech Athersys that reported that treatment of stroke patients with its product MultiStem was associated with a statistically significant improvement at 1-year. This sounds encouraging and the stock has spiked up as a result. However, there are some naysayers

About that Athersys stem cell stroke clinic trial PR… Read More »

Can Stemcentrx thrive as a biotech killing cancer stem cells?

September 9, 2015 / Professor Paul Knoepfler, Ph.D.

A stem cell biotech in the news this week was one that had mostly flown under the radar previously with aim to zap cancer stem cells. Stemcentrx has a focus on killing cancer stem cells as a novel approach to treating cancer. Antonio Regalado had a nice article yesterday on the company. He reports that Stemcentrx has

Can Stemcentrx thrive as a biotech killing cancer stem cells? Read More »

Tale of 7 stem cell biotech stock woes

July 23, 2015 / Professor Paul Knoepfler, Ph.D. / 11 Comments

To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those

Tale of 7 stem cell biotech stock woes Read More »

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc

June 27, 2015 / Heather Main / 1 Comment

The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »

Bioheart on the edge in 2015?

May 6, 2015 / Professor Paul Knoepfler, Ph.D.

Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy

Bioheart on the edge in 2015? Read More »

Was Fujifilm CDI acquisition a good move by the companies?

March 31, 2015 / Professor Paul Knoepfler, Ph.D. / 4 Comments

The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did

Was Fujifilm CDI acquisition a good move by the companies? Read More »

Advanced Cell Technology pub: Trial for Macular Degeneration

October 14, 2014 / Professor Paul Knoepfler, Ph.D. / 8 Comments

The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related

Advanced Cell Technology pub: Trial for Macular Degeneration Read More »

ACT reinventing itself with new name Ocata Therapeutics

September 12, 2014 / Professor Paul Knoepfler, Ph.D. / 6 Comments

Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently

ACT reinventing itself with new name Ocata Therapeutics Read More »

Interview with StemCells Inc. leadership on hot topics

August 31, 2014 / Professor Paul Knoepfler, Ph.D. / 5 Comments

StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought

Interview with StemCells Inc. leadership on hot topics Read More »

biotechs

Subscribe to Our Newsletter